ROSELINDE BOYNE: Open Payments
NPI 1669887881 · CHARLOTTE, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$504 in 28 payments from 15 companies in 2025. Trend: 2023 $502 · 2024 $503 · 2025 $504
Food & beverage: $504
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 8 | $137 |
| Axsome Therapeutics, Inc. | 2 | $53 |
| PFIZER INC. | 3 | $49 |
| Viatris Specialty LLC | 2 | $47 |
| Sumitomo Pharma America, Inc. | 2 | $40 |
| AstraZeneca Pharmaceuticals LP | 2 | $29 |
| GlaxoSmithKline, LLC. | 1 | $22 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $17 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $16 |
Products named: Auvelity, Rybelsus, YUPELRI, Ozempic, GEMTESA, ELIQUIS, AIRSUPRA, TRELEGY ELLIPTA.
Industry payments across MI — which companies pay providers there.
